0001209191-17-053538.txt : 20170920
0001209191-17-053538.hdr.sgml : 20170920
20170920211234
ACCESSION NUMBER: 0001209191-17-053538
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170918
FILED AS OF DATE: 20170920
DATE AS OF CHANGE: 20170920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Luke Nathaniel
CENTRAL INDEX KEY: 0001701440
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33882
FILM NUMBER: 171095014
MAIL ADDRESS:
STREET 1: C/O CASCADIAN THERAPEUTICS, INC.
STREET 2: 2601 4TH AVE., SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001412067
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 260868560
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: (206) 801-2100
MAIL ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: Oncothyreon Inc.
DATE OF NAME CHANGE: 20070927
FORMER COMPANY:
FORMER CONFORMED NAME: Biomira CORP
DATE OF NAME CHANGE: 20070911
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-18
0
0001412067
Cascadian Therapeutics, Inc.
CASC
0001701440
Walker Luke Nathaniel
C/O CASCADIAN THERAPEUTICS, INC.
2601 4TH AVE., SUITE 500
SEATTLE
WA
98121
0
1
0
0
SVP, Clinical Development
Stock Option (right to buy)
3.99
2017-09-18
4
A
0
50000
0.00
A
2027-09-18
Common Stock
50000
50000
D
Restricted Share Unit (RSU)
2017-09-18
4
A
0
12000
0.00
A
2021-09-18
Common Stock
12000
12000
D
The option vests and is exercisable at the rate of 1/4th of the total shares on September 18, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date.
Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.
Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date.
/s/ Julia M. Eastland as attorney-in-fact for Luke N. Walker
2017-09-20